Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2012.
“With the positive data from both Phase 3 trials of tavaborole for the treatment of onychomycosis, we anticipate filing an NDA around the middle of this year, and we will continue to evaluate commercialization options to maximize the value of tavaborole,” said David Perry, CEO of Anacor Pharmaceuticals. “We are looking forward to the results of the ongoing Phase 2 dose-ranging study of AN2728 in adolescents with atopic dermatitis later this month, and those results will help us determine the proper concentration and dosing of AN2728 for our anticipated Phase 3 trials.”
Fourth Quarter 2012 Highlights and Recent Developments
- Tavaborole – our lead topical antifungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.
- In the first quarter of 2013, we announced the results from two Phase 3 clinical trials in which tavaborole achieved statistically significant and clinically meaningful results on all primary and secondary endpoints.
- AN2728 – our lead topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis. Atopic dermatitis is a chronic rash characterized by inflammation and itching and affects an estimated 40 million people in the seven major pharmaceutical markets, including approximately 10% to 20% of infants and young children.
- In December 2012, we announced positive results from a Phase 2 safety, pharmacokinetics and efficacy trial of AN2728 in adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis. This was our second Phase 2 study of AN2728 in atopic dermatitis, and we currently have a third Phase 2 study ongoing, with results expected later this month.
- Eli Lilly and Company
- In December 2012, Lilly selected a second development candidate under our research and development agreement to create and develop new therapeutics for animal health. Under the terms of the collaboration, we received a $1.0 million payment for this achievement and are eligible to receive additional development and regulatory milestones as well as tiered royalties from the high single digits to the low double digits on future sales. Lilly is responsible for all further development of both candidates selected and related commercialization expenses for either or both candidates, if approved.
- In October 2012, GlaxoSmithKline (GSK) advised us that it had discontinued further development of AN3365, and all rights to this compound reverted to us. We are considering our options for further development, if any, of this compound.
- We continue to work with GSK on a tuberculosis program, which was initiated in 2011.
- In October 2012, we completed an underwritten public offering of 4,000,000 shares of our common stock with net proceeds of approximately $22.6 million.
- In October 2012, we filed a demand for arbitration regarding a breach of contract dispute between Valeant Pharmaceuticals International, Inc., successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS) and us, arising out of a master services agreement entered into by Anacor and DPS in March 2004 related to certain development services provided by DPS in connection with our efforts to develop our topical antifungal product candidate for the treatment of onychomycosis. We have asserted claims for breach of contract, breach of fiduciary duty, intentional interference with prospective business advantage and unfair competition. We are seeking injunctive relief and damages of at least $215.0 million. The hearing for the preliminary injunction has been set for May 6-8, 2013. We currently expect the resolution of the arbitration to occur in the second half of 2013.
- Tavaborole, our lead product candidate for the treatment of onychomycosis
- We expect to file a NDA for tavaborole in mid-2013.
- AN2728, our lead product candidate for the treatment of atopic dermatitis
- We expect data from the ongoing Phase 2 dose-ranging study in adolescents in March 2013.
- Subject to the results of our Phase 2 dose-ranging study, we expect to finalize our development plan to prepare to initiate a Phase 3 study in atopic dermatitis around year-end 2013.
- We anticipate the resolution of our arbitration with Valeant in the second half of 2013.
- We expect to choose a path for commercialization of tavaborole in the second half of 2013.
- Revenues for the quarter ended December 31, 2012 were $3.3 million, compared to $2.6 million for the comparable period in 2011. The increase in revenues was primarily due to the $1.0 million development milestone earned in the fourth quarter of 2012 under our collaboration with Lilly, partially offset by decreases in revenues from our neglected diseases programs. Revenues for 2012 were $10.7 million compared to $20.3 million in 2011. Revenue from GSK was $10.8 million in 2011, which was largely associated with the September 2011 amendment to our collaboration agreement, compared to revenue from GSK of $1.3 million in 2012, primarily for research funding. In addition, revenue from our neglected diseases programs decreased in 2012 as compared to 2011.
- Research and development expenses for the fourth quarter of 2012 were $12.0 million compared to $13.9 million for the comparable period in 2011. Research and development expenses for 2012 were $52.3 million compared to $56.1 million in 2011. The decrease in expenses in the last quarter of 2012 compared to the same quarter in 2011 was primarily due to lower clinical trial activity in our tavaborole program and a net decrease in activities under our research and development collaborations. The decrease in expenses for 2012 compared to 2011 was mainly due to less extensive manufacturing efforts for AN2728 in 2012, reduced AN2898 program activity as we concentrated our efforts on the development of AN2728 and a net reduction in our research and development collaboration activities. These decreases were partially offset by the increased tavaborole activity related to our regulatory and pre-commercialization activities as we prepare for our 2013 NDA filing.
- General and administrative expenses for the fourth quarter of 2012 were $2.8 million compared to $2.9 million for the comparable period in 2011. General and administrative expenses for 2012 were $11.6 million compared to $10.6 million in 2011. The increase for the year ended 2012 as compared to the same period in 2011 resulted primarily from increases in legal fees relating to intellectual property and corporate development activities, increases in our expenses for market research and other pre-commercialization activities for tavaborole and increased salaries and related expenses due to the hiring of additional personnel, partially offset by decreases in our stock compensation expense.
- Cash, cash equivalents and short-term investments totaled $45.5 million at December 31, 2012 compared to $50.7 million at December 31, 2011.
- We believe our cash, cash equivalents and short-term investments will be sufficient to meet our anticipated operating requirements until we file our NDA for tavaborole in onychomycosis, which we expect to occur in mid-2013.
ANACOR PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
| Three Months Ended
| Year Ended
|Contract revenue||$||3,288||$||2,596||$||10,740||$ 20,306|
|Research and development (1)||11,999||13,922||52,318||56,097|
|General and administrative (1)||2,762||2,870||11,614||10,552|
|Total operating expenses||14,761||16,792||63,932||66,649|
|Loss from operations||(11,473||)||(14,196||)||(53,192||)||(46,343||)|
|Loss on early extinguishment of debt||––||––||––||(313||)|
|Net loss||$||(12,476||)||$||(14,549||)||$||(56,087||)||$ (47,944||)|
|Net loss per common share – basic and diluted.||$||(0.36||)||$||(0.52||)||$||(1.76||)||$ (1.71||)|
|Weighted-average number of common shares used in calculating net loss per common share – basic and diluted||34,618,080||28,192,721||31,901,966||28,109,302|
(1) Includes the following noncash, stock-based compensation expenses:
|Research and development expenses||$||489||$||679||$ 1,973||$||2,594|
|General and administrative expenses||378||509||1,629||1,810|
ANACOR PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEET DATA
|Cash, cash equivalents and short-term investments||$||45,516||$||50,682|
|Total stockholders’ equity||4,811||13,899|
(1) Derived from the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.